Quarterly ResultMay 11, 2026, 04:13 PM
Erasca Reports Q1 2026 Results; Cash $409M; ERAS-0015 Data Positive
AI Summary
Erasca, Inc. reported its first quarter 2026 financial results, with a net loss of $183.4 million, or $(0.60) per share, primarily due to a $150 million in-process R&D expense for an expanded license agreement. Despite the increased loss, the company's cash, cash equivalents, and marketable securities stood at a robust $408.5 million, following a successful $258.8 million public offering in January 2026, extending its operational runway into the second half of 2028. The company also provided positive business updates, including robust preliminary monotherapy data for ERAS-0015 and anticipated data for ERAS-4001 in H2 2026, along with new clinical trial collaborations.
Key Highlights
- Cash, cash equivalents, and marketable securities were $408.5 million as of March 31, 2026.
- Net loss was $183.4 million, or $(0.60) per share, for the quarter ended March 31, 2026.
- Research and Development (R&D) expenses were $27.3 million, plus $150 million in-process R&D expense.
- General and Administrative (G&A) expenses were $10.6 million for the quarter.
- Cash, cash equivalents, and marketable securities are expected to fund operations into H2 2028.
- ERAS-0015 monotherapy expansion and combination data expected in H1 2027.
- ERAS-4001 Phase 1 preliminary monotherapy data expected in H2 2026.
- Completed an upsized public offering in January 2026, raising $258.8 million in gross proceeds.